Retatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday.
Retatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight…
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about…
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its…
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body…
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned…
